Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients

Antimicrob Agents Chemother. 2006 Jul;50(7):2553-6. doi: 10.1128/AAC.00092-06.

Abstract

We analyzed 3,475 human immunodeficiency virus sequences and 241 therapeutic histories. The L74I mutation was carried by 7% of viruses. L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Anti-HIV Agents / therapeutic use*
  • Benzoxazines
  • Cyclopropanes
  • Dideoxynucleosides / therapeutic use*
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV Reverse Transcriptase / genetics*
  • HIV-1 / drug effects
  • HIV-1 / enzymology*
  • HIV-1 / genetics
  • Humans
  • Mutation*
  • Oxazines / therapeutic use*
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Risk Factors

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Dideoxynucleosides
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • HIV Reverse Transcriptase
  • efavirenz
  • abacavir